CFDE Data Portal | Search CYREN

	Label	Description
	CYREN Gene (Entity type)	ENSG00000122783 - cell cycle regulator of NHEJ
	GSE233679 14 V 13 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE132369,GSE132371 3 V 0 CCCP HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 0 V 10 SULFORAPHANE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

CYREN

ENSG00000122783 - cell cycle regulator of NHEJ

GSE233679 14 V 13 NICOTINAMIDE HUMAN DN

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE132369,GSE132371 3 V 0 CCCP HUMAN UP

A Gene Set from LINCS

GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE48812 0 V 10 SULFORAPHANE HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.